This is different from traditional biotech approaches. Biotech, as you know it from a pharmaceutical perspective, is either petrochemistry, that means it's oil or gas as the core starting point broken down into fragments that people use as drugs, or it is something people have isolated from nature. We're kind of like a third way of making chemistry. So we basically take the best from nature, that is the enzymes, and we then optimize them so we can build small molecules. So we have the same design controls as if it was chemistry, but it is actually biology inspired. Think of it as brute forcing evolution. So evolution out in nature, that is one mutation per generation, and then over many, many, many generations and billions of years, you have evolution playing out. We basically do that computationally in a week, sit down and say, what are all the different combinations of genetic mutations, optimizations that could lead to a better enzyme that in the end can lead to this better production pathway. So we have a nutraceutical and a pharmaceutical double dip opportunity per molecule we work with because if we do the same thing as nature, it can lead to a pathway to getting over the counter. But especially when we optimize on the molecules so they become new to nature molecules, then obviously we do the safety testing.